Valo Health

End-to-end drug discovery and development platform integrating AI with human-centric data.

Valo Health operates an end-to-end drug discovery and development platform, called Opal, that integrates machine learning with large-scale human phenotypic and clinical data. The platform spans target discovery, molecular design, and translational development across cardiovascular, metabolic, oncology, and neurodegeneration programs.

Headquarters: Boston, United States
Founded: 2019
Compliance: SOC 2 Type II
Deployment options: cloud
Website: https://www.valohealth.com
LinkedIn: https://www.linkedin.com/company/valo-health

AI Use Cases

Hit Identification & Lead Optimization
Target Identification & Validation

Vendor Scorecard

93% — Complete coverage. Coverage score — how completely Atlas documents Valo Health across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.

Compliance & Validation — Documented

SOC 2 Type II

Deployment & Hosting — Documented

cloud

Pricing Transparency — Documented

Partnership / milestone based

Implementation & Onboarding — Documented

12+ months

Organization & Role Fit — Documented

Biotech Startup, Mid-Size Biotech, Large Pharma, Drug Discovery, R&D Leadership

Solution Scope — Documented

Molecular Generation, Real-World Evidence, Target Identification

Company Viability — Partially documented

Private, Founded 2019

Always ask the vendor

Not captured in Atlas data — confirm directly. Excluded from the score above.

Data Rights & IP

Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?

Model Credibility & Explainability

Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?

Clinical Trial Activity

2 registered trials where Valo Health is the lead sponsor. Source: ClinicalTrials.gov, verified 2026-07-29.

Phases: Phase 2 (2)

Top conditions studied: Myocardial Infarction, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy

Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) (NCT05327855, withdrawn)
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy (NCT05393284, unknown)

Evidence & Outcomes

Merck KGaA collaboration for Parkinson's disease drug discovery

Valo Health announced a collaboration with Merck KGaA, Darmstadt, Germany, to discover and develop novel treatments for Parkinson's disease and related disorders, applying Valo's human-data-driven Opal computational platform to target discovery.

press release (Valo Health) · 2024-10-09 — Partner: Merck KGaA, Darmstadt, Germany

Long-term partnership with nference to accelerate human-centric drug discovery

Valo Health and nference announced a long-term partnership combining Valo's human-centric drug discovery and development platform with nference's real-world data and analytics to accelerate the identification and validation of novel drug programs.

press release (Valo Health (Business Wire)) · 2025-03-18 — Partner: nference

Questions to Ask This Vendor

What human data sources power the Opal platform?
How are computational predictions validated in the lab?
How is IP structured in partnership programs?